drugset

drugset / Trial / NCT01755091

Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea

NCT01755091 ↗

Phase 2 Completed 75 enrolled University of Illinois at Chicago Hektoen Institute for Medical Research · collab National Heart, Lung, and Blood Institute (NHLBI) · collab Northwestern University · collab University of Chicago · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a proof of concept study to determine the safety and efficacy of dronabinol for the treatment of obstructive sleep apnea syndrome (OSA).

Timeline

Start: 2013-02
Primary completion: 2016-06
Completion: 2016-12-31

Publications

Carley DW, Prasad B, Reid KJ, Malkani R, Attarian H, Abbott SM, Vern B, Xie H, Yuan C, Zee PC. Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea. Sleep. 2018 Jan 1;41(1):zsx184. doi: 10.1093/sleep/zsx184.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dronabinol	Other / unclassified	2.5 mg	Oral
Subject	Dronabinol	Other / unclassified	10 mg	Oral

Indications